1.Clinical relationship between interstitial cystitis and female hormone imbalance
Bolong LIU ; Fei YANG ; Hailun ZHAN ; Meijiang MENG ; Xiangfu ZHOU
Chinese Journal of Urology 2013;(7):501-504
Objective To Investigate the clinical relationship between the interstitial cystitis and female hormone imbalance.Methods A retrospective analysis of 58 cases of IC female patients in our hospital from January 2006 to April 2012.The patients' age ranged from 21 to 76 years,and the average age was 40.2±12.4 years old.The suffering time of disease ranged from 9 to 120 months,and the average duration was 64.3±55.7 months.At the 1st,12th,22th day of the menstrual cycle,the O'Leary-Sant and PUF questionnaires were used to score,in order to analyze the relationship between IC symptoms and the menstrual cycle.The symptoms scores between postmenopausal patients and No menopause patients were compared.At the same time,the medical records and follow-ups were reviewed for all patients.Results 51 cases of IC premenopausal female patients suffered more urinary frequency,urgency,and bladder pain during the menstrual period.The proportion respectively were 54.9 % (28/51),60.8% (31/51).The O'Leary-Sant scores of the 1st day were more significant difference than the12th and the 22th day (P<0.05),but there was no significant difference between the 12th day and the 22th day (P>0.05).The PUF scores of the 1st day were significant different than the 12th and the 22th day (P<0.05),but there was no significant difference between the 12th day and the 22th day (P>0.05).The average scores of O'Leary-Sant and PUF in 7 postmenopausal patients were statistically significant lower than non-menopausal patients (P<0.05).The incidence of 58 cases with uterine fibroids,breast hyperplasia,ovarian cysts,endometriosis (48.3%,41.4%,5.2%,13.8%) were higher than the average persons (P=0.001,0.460,0.001,0.048),which were significantly higher than the incidence of the general population (30.0%,40.0%,0.3%,7.0%) excepting breast hyperplasia.Conclusions The symptoms of urinary frequency,urgency,and bladder pain in IC patients were more serious during the menstrual period than the other periods.The symptoms of the non-postmenopausal patients were more serious than the postmenopausal patients.The incidence of IC patients associated with hormone imbalance diseases was higher than the general persons,indicating that the fluctuation of female hormone level was likely to be one cause of IC onset.
2.A multicenter randomized phase II trial of domestic product of nrhTNF in the treatment of non-small cell lung cancer.
Qinghua ZHOU ; Mei HOU ; Lu LI ; Li REN ; Meng QIU ; Yuqiong YANG ; Wenxia HUANG ; Zhen CHEN ; Zhiqiang MENG ; Mingzhi SONG ; Mingzhong LI ; Enxiao LI ; Yi LI ; Yu YAO ; Zhiwen ZHENG ; Xing LIU ; Xiangfu ZHANG ; Huishan LU ; Maohong ZHANG ; Xiuwen WANG ; Xuejun YU
Chinese Journal of Lung Cancer 2003;6(1):42-45
BACKGROUNDTo evaluate and compare the effects and toxicity of the domestic product of nrhTNF combined with chemotherapy in the trial group and chemotherapy alone in the control group in the treatment of patients with non-small cell lung cancer (NSCLC).
METHODSNinety patients with NSCLC in multicenter were randomly devided into trial group and control group. Each group had 45 patients. Chemotherapy with CAP regimen was given for the patients in the trial group. Meanwhile, nrhTNF injection of 4×10⁶U/m ² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy course. Twenty-one days were as a cycle, 2 cycles were given each patients. Chemotherapy alone with CAP regimen was given in the control group. The chemothepeutic effects and toxicity were observed and compared between the two groups after the therapy.
RESULTSOf the 90 patients, 3 cases in each group were out of the trial because of economy. The other 84 cases (each group had 42 patients) could be used to analyze and evaluate the clinical effects and toxicity. The response rate of chemotherapy was 47.62% (20/42) in the trial group and 19.05% (8/42) in the control group (P=0.002) respectively. The KPS was 85.02±10.74 in the trial group, and 81.35±9.63 in the control group (P=0.038). No significant difference of degree III+IV toxicity was observed between the trial group and control group (P > 0.05). The side effects related to nrhTNF included slight fever, cold like symptoms, pain, and red and swelling in injection site. All of them were mild and didn't need any treatment and disappeared after the therapy.
CONCLUSIONSThe results demonstrate that the effects of domestic nrhTNF combined with chemotherapy can remarkably higher than that of chemotherapy alone in the treatment of NSCLC. It is able to increase the sensitivity to chemotherapy and improve the quality of life of the patients. The toxicity is also slight and is worth to expand clinical use, so as to further evaluate its effect and toxicity.
3.A multicenter randomized phase III trial of domestic product of rmhTNF in the treatment of non-small cell lung cancer.
Qinghua ZHOU ; Xi YAN ; Li REN ; Lu LI ; Meng QIU ; Yuqiong YANG ; Deyun LUO ; Wenxia HUANG ; Luming LIU ; Zhen CHEN ; Zhiqiang MENG ; Yajie WANG ; Qiang FU ; Yang XU ; Linjun YANG ; Mingzhong LI ; Enxiao LI ; Yi LI ; Yu YAO ; Xiangfu ZHANG ; Xing LIU ; Huishan LU ; Maohong ZHANG ; Xiuwen WANG ; Xuejun YU ; Fengzhan QIN ; Rongsheng ZHENG ; Yuqing CHEN ; Minghong BI
Chinese Journal of Lung Cancer 2003;6(4):264-267
BACKGROUNDTo evaluate and compare the effects and toxicity of the domestic product of recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy and chemotherapy alone in the treatment of patients with non-small cell lung cancer (NSCLC).
METHODSTwo hundred patients with NSCLC in multicenter were randomly devided into trial group (150 cases) and control group (50 cases). Chemotherapy with CAP regimen was given to the patients. Meanwhile, rmhTNF injection of 4×10⁶U/m² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy cycle in the trial group. The control patients received chemotherapy alone. Twenty-one days were as a cycle, 2 cycles were given to each patient. The chemotherapeutic effects and toxicity were observed and compared between the two groups after the therapy.
RESULTSof the 200 patients, 5 cases in the trial group and 3 cases in the control group were out of the trial because of economy. The other 192 cases (145 cases in the trial group and 47 cases in the control group) could be analyzed and evaluated the clinical effects and toxicity. The response rate of chemotherapy was 46.90% (68/145) in the trial group and 17.02% (8/47) in the control group respectively ( P =0.001). The KPS scores was 86.02±9.74 in the trial group, and 80.14±9.10 in the control group ( P =0.025). No significant difference of degree III+IV toxicity was observed between the two groups ( P > 0.05). The side effects related to rmhTNF included slight fever, cold-like symptoms, pain and red and swelling in the injection site. All of them were mild and didn't need any treatment and disappeared after the therapy. There were no severe abnormality of liver and kidney function and ECG in both groups.
CONCLUSIONSThe results demonstrate that the effects of domestic rmhTNF combined with chemotherapy are remarkably higher than that of chemotherapy alone in the treatment of NSCLC. rmhTNF can increase the sensitivity to chemotherapy and improve the quality of life of the patients with slight toxicity. Hence rmhTNF is worth expanding clinical use.
4.Multi-classification prediction model of lung cancer tumor mutation burden based on residual network.
Xiangfu MENG ; Chunlin YU ; Xiaolin YANG ; Ziyi YANG ; Deng LIU
Journal of Biomedical Engineering 2023;40(5):867-875
Medical studies have found that tumor mutation burden (TMB) is positively correlated with the efficacy of immunotherapy for non-small cell lung cancer (NSCLC), and TMB value can be used to predict the efficacy of targeted therapy and chemotherapy. However, the calculation of TMB value mainly depends on the whole exon sequencing (WES) technology, which usually costs too much time and expenses. To deal with above problem, this paper studies the correlation between TMB and slice images by taking advantage of digital pathological slices commonly used in clinic and then predicts the patient TMB level accordingly. This paper proposes a deep learning model (RCA-MSAG) based on residual coordinate attention (RCA) structure and combined with multi-scale attention guidance (MSAG) module. The model takes ResNet-50 as the basic model and integrates coordinate attention (CA) into bottleneck module to capture the direction-aware and position-sensitive information, which makes the model able to locate and identify the interesting positions more accurately. And then, MSAG module is embedded into the network, which makes the model able to extract the deep features of lung cancer pathological sections and the interactive information between channels. The cancer genome map (TCGA) open dataset is adopted in the experiment, which consists of 200 pathological sections of lung adenocarcinoma, including 80 data samples with high TMB value, 77 data samples with medium TMB value and 43 data samples with low TMB value. Experimental results demonstrate that the accuracy, precision, recall and F1 score of the proposed model are 96.2%, 96.4%, 96.2% and 96.3%, respectively, which are superior to the existing mainstream deep learning models. The model proposed in this paper can promote clinical auxiliary diagnosis and has certain theoretical guiding significance for TMB prediction.
Humans
;
Lung Neoplasms/pathology*
;
Carcinoma, Non-Small-Cell Lung/genetics*
;
Mutation
;
Adenocarcinoma of Lung/genetics*
;
Biomarkers, Tumor/genetics*